Opdivo® (nivolumab) – New indication
April 16, 2021 - Bristol Myers Squibb announced the FDA approval of Opdivo (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
Top